Blockchain Registration Transaction Record

Alpha Cognition Inc. Achieves Milestones in 2025 with Strong Financial Performance and Promising Product Development

Stonegate Capital Partners provides an update on Alpha Cognition Inc. (NASDAQ: ACOG) and its achievements in 2025, including FDA approval for ZUNVEYL and promising developments in treating Alzheimer's and traumatic brain injury. The company's strong financial performance and strategic partnerships indicate potential for continued growth and positive impact on patient care.

This news matters as it highlights the significant progress made by Alpha Cognition Inc. in advancing its lead product, ZUNVEYL, for Alzheimer's and traumatic brain injury. The successful fundraising, uplisting to NASDAQ, and strategic partnerships position the company for continued growth and potential impact on patients suffering from these conditions.